Hadassah Medical CenterHadassah Medical Center
   Home    About    Treatment In Israel    Contact 
Home > Physicians, Researchers

Dr. Hilla Giladi, Ph.D.

Updated February 2008

 

 

 

Laboratory Chief

Goldyne Savad Institute of Gene Therapy

Phone:  972-2-677-7998

Fax: 972-2-643-0982

Email:  giladi@hadassah.org.il

 

Position

1998- Laboratory Chief, Goldyne Savad Institute of Gene Therapy

 

Affiliation

Hadassah-Hebrew University Medical Center, Jerusalem, Israel

 

Education

 

1967 - B.Sc. - Hebrew University of Jerusalem Faculty of Life Science, Jerusalem, Israel.

 

1970 - M.Sc. - Hebrew University of Jerusalem, Institute of Microbiology. Research done in the laboratory of Prof. Y. Becker, Department of Virology. Thesis: "Protein synthesis of the trachoma agent."

 

1980 - Ph.D. - University of Chicago, Chicago, Ill., Department of Biology. Research done in the laboratory of Prof. Niza Frenkel. Thesis: "Biological and structural properties of defective interfering particles of herpes simplex virus."

 

Research interests

 

Development of adeno and lentiviral vectors for transduction of hepatocytes for treatment of liver diseases; induction of apoptosis in hepatitis C infected cells;

 

RNA interference of HBV gene expression; development of animal models of hepatitis C viral infection.

 

Selected recent publications

 

Khvalevsky E, Rivkin L, Rachmilewitz J, Galun E, Giladi H. 2007. TLR3 signaling in a hepatoma cell line is skewed towards apoptosis. J Cell Biochem Jan 22

 

Condiotti R, Curran MA, Nolan GP, Giladi H, Ketzinel-Gilad M, Gross E, Galun E. 2004. Prolonged liver-specific transgene expression by a non-primate lentiviral vector. Biochem Biophys Res Commun. Jul 30;320(3):998-1006.

 

Giladi H, Ketzinel-Gilad M, Rivkin L, Felig Y, Nussbaum O, Galun E. 2003. Small interfering RNA inhibits hepatitis B virus replication in mice. Mol Ther Nov;8(5):769-76.

 

Beider K, Nagler A, Wald O, Franitza S, Dagan-Berger M, Wald H, Giladi H, Brocke S. 2003. Involvement of CXCR4 and IL-2 in the homing and retention of human NK and NK T cells  to the bone marrow and spleen of NOD/SCID mice. Blood, 102(6):1951-8.

 

Ohana P, Bibi O, Matouk I, Levy C, Birman T, Ariel I, Schneider T, Ayesh S, Giladi H., Laster M, de Groot N, Hochberg A. 2002. Use of H19 regulatory sequences for targeted gene therapy in cancer. Int J Cancer 98(5):645-50.

 

Abdul-Ghani, R, Ohana P, Matouk I, Ayesh S, Laster M, Bibi O, Giladi H, Molnar-Kimber K, Sughayer MA, de Groot N, Hochberg A. 2000. Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of Cancer cells. Mol Therapy 2, 539-544.

 

Giladi H, Koby S, Prag G, Engelhorn M, Geiselmann J, Oppenheim AB. 1998. Participation of IHF and a distant UP element in the stimulation of the phage lambda PL promoter. Mol Microbiol 30:443-51.

 

Obuchowski M, Shotland Y, Koby S, Giladi H, Gabig M, Wegrzyn G, Oppenheim AB. 1997. Stability of CII is a key element in the cold stress response of bacteriophage lambda infection. J Bacteriol 179:5987-91.

 

Obuchowski M, Giladi H, Koby S, Szalewska-Palasz A, Wegrzyn A, Oppenheim AB, Thomas MS., Wegrzyn G. 1997. Impaired lysogenisation of the Escherichia coli rpoA341 mutant by bacteriophage lambda is due to the inability of CII to act as a transcriptional activator. Mol Gen Genet 254:304-11.

 

Research group

 

Condiotti, Reba, M.Sc. (investigator) Phone: 677-7927

Ketzinel-Gilad, Mali, Ph.D. Phone: 677-7944/7559

Rivkin, Mila, B.Sc. Phone: 677-7944

Elina Khvalevsky, M.Sc. Phone: 677-7944

 

RESEARCH SUMMARY

 

As Laboratory Chief, I direct and coordinate the operations of the activities taking place at the Gene Therapy Institute regarding liver-directed gene therapy including the development of delivery methods, animal models, novel vaccination approaches and specific therapeutics.




Dr. Hilla Giladi


            
     
 


         Powered by